Pfizer Assembling New Commercial Team For Move Into Dermatology

Pfizer Inc. is building a specialized dermatology sales force as it moves into the therapy area as part of a broader strategy in inflammation and immunology. The company could launch its first drug in dermatology – crisaborole for atopic dermatitis – early next year, and Pfizer expects the drug to anchor a dermatology franchise.

Crisaborole, which Pfizer acquired earlier this year with the acquisition of Anacor Pharmaceuticals Inc. for $5.2bn, is pending approval...